

Facility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact Sara Rothman (CDER) at 301-796-3110.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

**April 2016
Compounding and Related Documents**

Facility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry

*Additional copies are available from:
Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov*

<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

**April 2016
Compounding and Related Documents**

Contains Nonbinding Recommendations

Draft — Not for Implementation

TABLE OF CONTENTS

I. INTRODUCTION..... 1
II. BACKGROUND..... 1
III. POLICY..... 3

1 **Facility Definition Under Section 503B of the**
2 **Federal Food, Drug, and Cosmetic Act**
3
4 **Guidance for Industry¹**
5

6
7 This draft guidance, when finalized, will represent the current thinking of the Food and Drug
8 Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not
9 binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the
10 applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible
11 for this guidance as listed on the title page.
12

13
14 **I. INTRODUCTION**
15

16 This guidance is intended for entities that are registered or are considering registering with the
17 Food and Drug Administration (FDA or Agency) as an outsourcing facility under section 503B
18 of the Federal Food, Drug, and Cosmetic Act (FD&C Act).² Section 503B defines an
19 outsourcing facility, in part, as “a facility at one geographic location or address.” FDA has
20 received questions from outsourcing facilities and other stakeholders about the meaning of this
21 term, such as whether multiple suites used for compounding human drugs at a single street
22 address constitute one or multiple facilities, or whether a single location where human drugs are
23 compounded can be subdivided into separate operations compounding under different standards.
24 FDA is issuing this guidance to answer these questions.
25

26 In general, FDA’s guidance documents do not establish legally enforceable responsibilities.
27 Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only
28 as recommendations, unless specific regulatory or statutory requirements are cited. The use of
29 the word *should* in Agency guidances means that something is suggested or recommended, but
30 not required.
31

32 **II. BACKGROUND**
33

34 Section 503B, added to the FD&C Act by the Drug Quality and Security Act in 2013, created a
35 new category of compounders called *outsourcing facilities*. Section 503B describes the
36 conditions that must be satisfied for human drug products compounded by or under the direct

¹ This guidance has been prepared by multiple offices in the Center for Drug Evaluation and Research (CDER) and in consultation with the Office of Regulatory Affairs at the Food and Drug Administration.

² A new section 503B was added to the FD&C Act by the Drug Quality and Security Act (DQSA). See Pub. L. No.113-54, § 102(a), 127 Stat. 587, 587-588 (2013).

Contains Nonbinding Recommendations

Draft — Not for Implementation

37 supervision of a licensed pharmacist in an outsourcing facility to qualify for exemptions from
38 three sections of the FD&C Act:

39

- 40 • section 502(f)(1) (concerning labeling requirements);
- 41 • section 505 (concerning drug approval requirements); and
- 42 • section 582 (concerning Drug Supply Chain Security Act requirements).

43

44 Section 503B(d)(4) of the FD&C Act defines an outsourcing facility as a facility at one
45 geographic location or address that— (i) is engaged in the compounding of sterile drugs; (ii) has
46 elected to register as an outsourcing facility; and (iii) complies with all of the requirements of
47 this section. In addition, an outsourcing facility is not required to be a licensed pharmacy, and it
48 may or may not obtain prescriptions for identified individual patients.³ Because drugs
49 compounded by outsourcing facilities are not exempt from section 501(a)(2)(B) of the FD&C
50 Act, outsourcing facilities are subject to current good manufacturing practice (CGMP)
51 requirements.^{4,5}

52

53 One of the conditions that must be met for a compounded drug to qualify for the exemptions
54 under section 503B is that it must be compounded in an outsourcing facility in which the
55 compounding of drugs occurs only in accordance with this section (section 503B(a)(11)). FDA’s
56 final guidance document, *For Entities Considering Whether to Register As Outsourcing
57 Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act*,⁶ clarifies that:

58

59 If you register a facility as an outsourcing facility, you are indicating your intent for the
60 facility’s compounded drugs to be regulated under section 503B of the FD&C Act.
61 Under section 503B(a)(11), a compounded drug can only qualify for the exemptions from
62 sections 502(f)(1), 505, and 582 of the FD&C Act if **all** of the facility’s compounded
63 drugs are compounded in accordance with section 503B (page 4).

64

65 The guidance further states that:

66

³ See section 503B(d)(4)(C).

⁴ See section 503B(a).

⁵ FDA has issued a draft guidance entitled, *Current Good Manufacturing Practice — Interim Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act* (“Interim CGMP Guidance”). The Interim CGMP Guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.

All FDA guidances are available on the FDA guidance Webpage at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>. FDA updates guidances regularly. To ensure that you have the most recent version, please check this web page.

⁶ See the guidance *For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act*.

Contains Nonbinding Recommendations

Draft — Not for Implementation

67 By registering as an outsourcing facility, an entity is electing to have its compounded
68 drugs regulated under section 503B of the FD&C Act, not section 503A. Drugs
69 compounded at an outsourcing facility are not eligible for the exemptions provided in
70 section 503A, even if the conditions in that section are met with respect to the particular
71 drug (page 5).

72
73 Some outsourcing facilities compound drugs both according to patient-specific prescriptions as
74 well as in response to orders that are not patient-specific, as section 503B permits them to do.⁷
75 FDA has been asked whether an outsourcing facility can create a separate area within its facility
76 for compounding according to patient specific prescriptions under section 503A, and not follow
77 CGMP requirements in that area. For example, can the drugs be compounded according to
78 patient-specific prescriptions in an adjacent area or room, or in a separate suite, but with the
79 same staff and the same components used in 503B compounding? The CGMP regulations⁸
80 contain requirements for facility design, staff training and competency testing, control of
81 incoming components, aseptic processing, air quality, environmental monitoring, and related
82 requirements designed to ensure the quality of the finished product. The application of different
83 CGMP requirements or the different conditions in section 503A and 503B to commingled
84 compounding activities can cause confusion about what requirements apply and could lead to the
85 production of substandard drugs.

86
87 For that reason, and because it is a condition of eligibility for the exemptions in section 503B
88 that all of the drug products compounded in an outsourcing facility must be compounded in
89 accordance with section 503B and with CGMP requirements, this guidance clarifies what
90 constitutes a “facility.”

91 92 **III. POLICY**

93
94 Section 503B(d) defines an outsourcing facility, in part, as “a facility at one geographic location
95 or address.” FDA interprets “facility at one geographic location or address” to mean a business
96 or other entity under one management, direct or indirect, engaged in human drug compounding
97 at a geographic location or street address. The agency considers all activities, equipment,
98 appurtenances, and materials part of such a facility if they are related to human drug
99 compounding under the supervision of the facility’s management at the same street address, or in
100 the same building, or in buildings located in close proximity to one another.

101
102 As noted above, all drug products compounded in an outsourcing facility are regulated under
103 section 503B⁹ and subject to CGMP requirements.¹⁰ These conditions cannot be avoided by
104 segregating or subdividing compounding within an outsourcing facility. For example, even if an

⁷ See note 3, *supra*.

⁸ See CGMP regulations at Title 21, Parts 210 and 211 of the Code of Federal Regulations.

⁹ See section 503B(a)(11).

¹⁰ See section 503B(a).

Contains Nonbinding Recommendations

Draft — Not for Implementation

105 outsourcing facility divides its site at one street address into multiple sections with temporary or
106 permanent physical barriers, conducts patient-specific and non-patient specific compounding in
107 different areas (e.g., in different hoods or different rooms), or conducts patient specific and non-
108 patient specific compounding on different days or different times of the day, all of the drug
109 products compounded at that street address must meet the conditions of section 503B or none of
110 the outsourcing facility's drug products would qualify for the exemptions in section 503B.
111 Furthermore, all of the drug products compounded at that street address must be compounded in
112 accordance with CGMP requirements or the outsourcing facility could be cited for violations of
113 section 501(a)(2)(B) of the FD&C Act.

114

A. Segregating Compounding of Drug Products Under Section 503A From 116 Compounding of Drug Products Under Section 503B

117

118 FDA is interpreting facility in this way to be consistent with the intent of section 503B. To be
119 eligible for the exemptions in section 503B(a), a drug product must be compounded in an
120 outsourcing facility in which drugs are compounded only in accordance with section 503B (see
121 section 503B(a)(11)). Outsourcing facilities may or may not obtain prescriptions for identified
122 individual patients, and they are not subject to the interstate distribution restrictions in section
123 503A. Therefore, the intent of this provision is to ensure that all drugs compounded at an
124 outsourcing facility without the restrictions in section 503A (e.g., the prescription requirement
125 and the restrictions on interstate distribution) are compounded in accordance with CGMP
126 requirements, labeled appropriately, subject to adverse event reporting, and otherwise
127 compounded in accordance with the conditions of section 503B.

128

129 If compounding under sections 503A and 503B were to take place in the same geographic
130 location or address, it could appear that all drug products compounded in the outsourcing facility
131 were being made under higher standards, when in fact some or all were made under lesser
132 controls (e.g., the drugs produced under the conditions of 503A would not be produced in
133 accordance with CGMP requirements).

134

135 In addition, this definition is designed to prevent commingling of compounding activities under
136 sections 503A and 503B to evade the conditions of section 503B and CGMP requirements. A
137 drug product compounded under section 503A may be indistinguishable from a drug product
138 compounded under section 503B except for the conditions under which it is compounded. It is
139 important to be able to follow the production of drug products compounded in an outsourcing
140 facility to ensure that the products are made under CGMP requirements from the time the bulk
141 drug substances are received at the facility through production of the finished dosage form. If a
142 firm compounds drug products in the same general location under different standards, it will be
143 difficult to ensure that all of the products were made under the correct standards, particularly if
144 the activities are commingled (e.g., because compounding under both standards draws on the
145 same supplies, equipment, personnel, storage, or processing areas), or if compounded drug
146 products are marketed under the same firm name or from the same location. And because drug
147 products compounded under section 503A must be compounded in accordance with a
148 prescription while drug products made under section 503B may or may not be compounded in
149 accordance with a prescription, if the drug products are made in neighboring suites in the same

Contains Nonbinding Recommendations

Draft — Not for Implementation

150 building, it may be impossible to determine whether a prescription was obtained for the a
151 particular product before it was distributed. The agency’s interpretation also provides clarity
152 during inspections with regard to which standards apply to the location that is being inspected.
153

154 It is in the best interest of the public health to be clear about the separation between 503A and
155 503B facilities to ensure that those obtaining the drugs will know the standards under which they
156 were compounded. Furthermore, the public health is best served, and an important objective of
157 section 503B is achieved, if all drug products compounded in an outsourcing facility, whether
158 patient-specific or non-patient specific, are compounded in accordance with CGMP requirements
159 and other requirements imposed in section 503B of the FD&C Act.
160

B. Compounding Drug Products Under Section 503B and Conventionally Manufacturing Drug Products at the Same Facility

164 If a conventional manufacturer registers a facility as an outsourcing facility and makes both
165 approved drug products and compounded drug products in the outsourcing facility, the
166 compounded drug products would need to meet the conditions of section 503B to qualify for the
167 exemptions from sections 502(f)(1), 505, and 582.¹¹
168

169 All of the drug products produced at the facility would be subject to the CGMP requirements in
170 21 CFR parts 210 and 211. As stated above,¹² FDA has issued a draft guidance that, when
171 finalized, will describe FDA’s expectations regarding outsourcing facilities and these CGMP
172 requirements. When a facility both manufactures conventional drug products and compounds
173 drug products under section 503B, the policies described in this guidance would apply to the
174 facility’s compounded drug products, except with respect to CGMP requirements that must be
175 implemented throughout a manufacturing facility and cannot be applied differently to different
176 drug products in the same facility, such as environmental monitoring and pressure differential
177 monitoring requirements.
178

179 The compounding of drug products under section 503B and the manufacture of approved drug
180 products in the same facility does not present the complications described above regarding the
181 compounding of drug products under sections 503A and 503B in the same facility. For example,
182 an outsourcing facility could not commingle its compounded and approved drug products to
183 avoid manufacturing the approved drug products in accordance with applicable CGMP
184 requirements or to avoid compounding drug products in accordance with the conditions of
185 section 503B. An outsourcing facility’s compounded drug products are easily differentiated
186 from its approved drug products; the approved drug products are the subject of approved drug
187 applications and are listed with FDA under section 510 of the FD&C Act, while the compounded
188 drug products are unapproved and are generally not listed. Furthermore, outsourcing facilities

¹¹ We do not read “compounding” in section 503B(a)(11) of the Act to refer to the manufacture of an approved drug product. Therefore, a drug product may be compounded in an outsourcing facility in accordance with section 503B even if an approved drug product is manufactured in that outsourcing facility not in accordance with section 503B.

¹² See footnote 5.

Contains Nonbinding Recommendations

Draft — Not for Implementation

189 must label compounded drug products with the statement, “This is a compounded drug,”¹³ so
190 purchasers of compounded drug products from an outsourcing facility that also manufactures
191 approved drug products will know that the drug products that they purchased were compounded.
192 FDA verifies during inspections that outsourcing facilities are producing their compounded and
193 approved drug products in accordance with the applicable standards, including that the drug
194 products are labeled appropriately.

¹³ See section 503B(a)(10).